Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Stock Has Average Price Target of $6.40

Key Points

• Analysts rate Milestone Pharmaceuticals “Moderate Buy”, with four buy ratings, one strong buy, one hold and one sell. The average 12-month price target is $6.40.
• Institutional investors own approximately 86.18% of the stock, with several firms increasing their positions or initiating new stakes.
• MIST opened at $0.79, near its 52-week low of $0.71, while its latest quarterly results missed expectations: an adjusted loss of $0.21 per share versus the $0.20 consensus and revenue of $0.56 million versus $0.82 million expected.

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $6.40.

A number of equities analysts have recently commented on MIST shares. HC Wainwright reaffirmed a "buy" rating on shares of Milestone Pharmaceuticals in a report on Thursday, September 3rd. Zacks Research upgraded shares of Milestone Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Monday, July 13th. Cantor Fitzgerald initiated coverage on shares of Milestone Pharmaceuticals in a research note on Thursday, August 20th. They set an "overweight" rating and a $3.00 price target for the company. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Milestone Pharmaceuticals in a research report on Monday.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Valeo Financial Advisors LLC grew its holdings in shares of Milestone Pharmaceuticals by 12.2% during the third quarter. Valeo Financial Advisors LLC now owns 146,699 shares of the company's stock worth $127,000 after buying an additional 16,000 shares during the last quarter. RVW Wealth LLC purchased a new stake in Milestone Pharmaceuticals during the 3rd quarter valued at approximately $994,000. HighTower Advisors LLC raised its stake in Milestone Pharmaceuticals by 100.0% during the 2nd quarter. HighTower Advisors LLC now owns 20,000 shares of the company's stock valued at $27,000 after acquiring an additional 10,000 shares during the last quarter. Guardian Wealth Advisors LLC NC lifted its position in Milestone Pharmaceuticals by 21.1% during the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 339,450 shares of the company's stock worth $455,000 after acquiring an additional 59,200 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new stake in Milestone Pharmaceuticals during the 2nd quarter worth approximately $134,000. 86.18% of the stock is owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Trading Up 0.8%

NASDAQ:MIST opened at $0.79 on Friday. The company has a market capitalization of $98.92 million, a PE ratio of -1.15 and a beta of 1.01. Milestone Pharmaceuticals has a 52-week low of $0.71 and a 52-week high of $3.06. The stock's 50 day moving average price is $0.99 and its 200 day moving average price is $1.29. The company has a quick ratio of 7.92, a current ratio of 8.13 and a debt-to-equity ratio of 3.25.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). The business had revenue of $0.56 million during the quarter, compared to the consensus estimate of $0.82 million. On average, research analysts anticipate that Milestone Pharmaceuticals will post -0.84 EPS for the current year.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular conditions. The company's lead product candidate is etripamil, a short-acting calcium channel blocker formulated as a nasal spray and designed for rapid, patient-administered treatment.

Etripamil has been studied primarily for paroxysmal supraventricular tachycardia (PSVT), a condition characterized by episodes of abnormally rapid heart rate. The product is intended to provide patients with an option for treating episodes outside of a hospital or clinic, potentially reducing the need for emergency medical intervention.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.